METASTATIC PROSTATE CANCER
Clinical trials for METASTATIC PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 6-Month shot shows promise in taming prostate cancer
Disease control CompletedThis study tested a single injection of triptorelin pamoate that lasts 6 months in 195 Chinese men with advanced or metastatic prostate cancer. The goal was to lower testosterone to castrate levels, which helps control cancer growth. The treatment was effective and safe, offering…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New radioactive cocktail shows promise for tough prostate cancers
Disease control CompletedThis study tested a radioactive drug (I-131-1095) plus a standard hormone therapy (enzalutamide) in 120 men with advanced prostate cancer that had stopped responding to another treatment (abiraterone). The goal was to see if the combination could shrink tumors and lower PSA level…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
Virtual reality hypnosis tested to ease chemo anxiety in prostate cancer
Symptom relief CompletedThis study looked at whether using hypnosis in virtual reality could help reduce anxiety in men with metastatic prostate cancer during their chemotherapy treatments. 53 men receiving a standard chemotherapy drug (docetaxel) were randomly assigned to either get the VR hypnosis or …
Matched conditions: METASTATIC PROSTATE CANCER
Phase: NA • Sponsor: Saint-Gregoire Private Hospital Center • Aim: Symptom relief
Last updated May 17, 2026 04:16 UTC
-
Can two drugs make prostate cancer scans clearer?
Knowledge-focused CompletedThis study tested whether taking dasatinib alone or with darolutamide for 14 days can change the appearance of PSMA PET scans in men with metastatic prostate cancer. Four men with low PSMA uptake on their scans participated. The goal was to learn more about how PSMA levels change…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE2 • Sponsor: St Vincent's Hospital, Sydney • Aim: Knowledge-focused
Last updated May 17, 2026 04:37 UTC